Search
Vecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or … A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium.
Products: Vecuronium Bromide for Injection, VECURONIUM BROMIDE FOR INJECTIONLevobupivacaine
go.drugbank.com/drugs/DB01002ApprovedInvestigationalWithdrawnIn particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. … It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal
Synonyms: L-BUPIVACAINE, L-(−)-bupivacainePotassium perchlorate
go.drugbank.com/drugs/DB09418ApprovedWithdrawnThe therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome [L2364]. … The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365].
Pembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [A7624] In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: KEYTRUDA SOLUTION FOR INFUSION 25MG/ML, Keytruda 100mg Solution for InfusionRebamipide
go.drugbank.com/drugs/DB11656ApprovedInvestigationalRebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
Categories: Compounds used in a research, industrial, or household setting, Drugs for Acid Related DisordersTechnetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalTechnetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. … infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.
Categories: Compounds used in a research, industrial, or household settingProducts: Kit for the Preparation of Technetium Tc99m SestamibiHistamine
go.drugbank.com/drugs/DB05381ApprovedInvestigationalIt is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. … A depressor amine derived by enzymatic decarboxylation of histidine.
Mixtures: MIKES Ponos Pain Relief Cream Roll-OnCategories: Tests for Gastric SecretionDebrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Nesiritide
go.drugbank.com/drugs/DB04899ApprovedInvestigationalWithdrawnNesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). … Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.
Categories: Vasodilators Used in Cardiac DiseasesTegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalIt is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with [DB09257] and [DB03209], or along with [DB00544] as [DB09327]. … Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by
International brands: ESUEEW AN TCategories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index